Clene Inc.

Equities

CLNN

US1856341029

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
0.3399 ^USD	-1.90%		-2.66%	+14.60%

Apr. 16	Clene Inc. and Clene Nanomedicine, Inc. Presented the Phase 2 VISIONARY-MS Long term Extension Study Results at the 2024 American Academy of Neurology Annual Meeting in Denver	CI
Mar. 15	Clene Inc. Announces Peer-Reviewed Publication Characterizing the Protein Corona of the Investigational Neurodegenerative Disease Drug, CNM-Au8	CI

Clene Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022

August 15, 2022 at 07:03 am EDT

Clene Inc. reported earnings results for the second quarter and six months ended June 30, 2022. For the second quarter, the company reported revenue was USD 0.035 million compared to USD 0.201 million a year ago. Net loss was USD 4.53 million compared to USD 3.35 million a year ago. Basic loss per share from continuing operations was USD 0.07 compared to USD 0.05 a year ago.
For the six months, revenue was USD 0.065 million compared to USD 0.414 million a year ago. Net loss was USD 17.89 million compared to USD 43.11 million a year ago. Basic loss per share from continuing operations was USD 0.28 compared to USD 0.71 a year ago.

Latest news about Clene Inc.

Clene Inc. and Clene Nanomedicine, Inc. Presented the Phase 2 VISIONARY-MS Long term Extension Study Results at the 2024 American Academy of Neurology Annual Meeting in Denver	Apr. 16	CI
Clene Inc. Announces Peer-Reviewed Publication Characterizing the Protein Corona of the Investigational Neurodegenerative Disease Drug, CNM-Au8	Mar. 15	CI
Clene Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 13	CI
North American Morning Briefing : Stock Futures -2-	Mar. 11	DJ
Clene Reports Significant Survival Benefit with Cnm-Au8® Treatment in Als Eap Compassionate Use Programs	Feb. 22	CI
Clene Inc. Reports Significant Improvement in Vision and Cognition with Cnm-Au8®? Treatment in Vision-MS Trial	Jan. 08	CI
US FDA finds Clene's trial data for ALS drug to be insufficient	Dec. 21	RE
Clene Inc. and Clene Nanomedicine Inc. Announce Peer-Reviewed Publication Describing CNM-Au8 Brain Target Engagement in Neurodegenerative Diseases	Dec. 14	CI
Earnings Flash (CLNN) CLENE Reports Q3 Revenue $108M	Nov. 07	MT
Clene Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 07	CI
North American Morning Briefing : Stocks Look to -2-	Nov. 06	DJ
Sector Update: Health Care Stocks Advancing Late Afternoon	23-10-05	MT
Sector Update: Health Care	23-10-05	MT
Clene Shares Jump After Being Awarded $45.1 Million Government Grant for Investigational ALS Drug	23-10-05	MT
Clene Awarded $45.1 Million Government Grant to Fund EAP for Investigational ALS Drug	23-10-05	MT
Clene Files for Potential Secondary Offering of Up to 3 Million Common Shares	23-09-25	MT
Clene Inc. Announces Executive Changes	23-09-19	CI
Certain Warrants of Clene Inc. are subject to a Lock-Up Agreement Ending on 15-SEP-2023.	23-09-14	CI
Certain Stock Options of Clene Inc. are subject to a Lock-Up Agreement Ending on 15-SEP-2023.	23-09-14	CI
Certain Common Stock of Clene Inc. are subject to a Lock-Up Agreement Ending on 15-SEP-2023.	23-09-14	CI
Transcript : Clene Inc. Presents at H.C. Wainwright 25th Annual Global Investment Conference, Sep-11-2023 11:00 AM	23-09-11
Earnings Flash (CLNN) CLENE Posts Q2 Revenue $269,000	23-08-14	MT
Clene Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14	CI
North American Morning Briefing : Stock Futures Firmer Despite More China Stress	23-08-14	DJ
Benchmark Cuts Price Target on Clene to $5 From $7, Maintains Buy Rating	23-06-30	MT

Chart Clene Inc.

Duration

Period

More charts

Company Profile

Clene Inc. is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis, Parkinson's disease and multiple sclerosis. It specializes in the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its CNM-Au8 is an investigational first-in-class therapy that improves central nervous system cells' survival and function via a mechanism that targets mitochondrial function and the nicotinamide adenine dinucleotide pathway while reducing oxidative stress. Its CNM-ZnAg is a broad-spectrum antiviral, antibacterial agent comprised of zinc (Zn2+) and silver (Ag+) ions under development to treat infectious disease and to provide immune support for symptom resolution. Its CNM-AgZn17 is a gel polymer suspension of Zn2+ and Ag+ under development for treatment of infectious diseases and to support wound healing.

Sector

Biotechnology & Medical Research

Calendar

2024-05-05 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Clene Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.3465 USD

Average target price

5 USD

Spread / Average Target

+1,343.00%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
CLENE INC.	+14.60%	44.5M
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.71B
ARGENX SE	+1.69%	22.02B
BIONTECH SE	-17.37%	20.9B
GENMAB A/S	-9.30%	17.85B
WUXI APPTEC CO., LTD.	-41.01%	16.21B
BEIGENE, LTD.	-14.85%	15.52B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.86B
SAREPTA THERAPEUTICS, INC.	+33.54%	12.04B

Bio Therapeutic Drugs